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birch, mugwort, Parietaria and olive pollen, dog, cat, horse, 
 Cladosporium herbarum , house dust mite and flour mite). At-
opy was defined as a positive result in the Phadiatop test ac-
cording to guidelines by the manufacturer. The prevalence 
rates of atopy, self-reported allergic rhinitis and doctor’s di-
agnosed asthma were evaluated by sex and age group ( ≤ 60 
or >60 years).  Results: 7,667 subjects (men = 3,692/women = 
3,975) participated in the follow-up by responding to a de-
tailed questionnaire (80% of SAPALDIA 1 participants). Phad-
iatop results were available  for 5,835 participants (men = 
2,839/women = 2,996). Prevalence rates of atopy (Phadiatop 
positive) were 36.4% in men aged  ≤ 60 years versus 26.2% in 
men aged >60 years and 30.6 and 18.1% in women, respec-
tively (both p < 0.001). Prevalence rates of self-reported al-
lergic rhinitis in subjects >60 years old were 13.0% for men 
and 15.4% for women (p = 0.12), and for doctor’s diagnosed 
asthma 6.6% versus 7.6%, respectively (p = 0.40). Both rhini-
tis and asthma prevalences were higher in persons <60 
years. The results were not sensitive to potential bias from 
nonparticipation at follow-up as demonstrated by imputa-
tion of sex- and age-specific allergic rhinitis and asthma 
among nonparticipants.  Conclusions: According to our esti-
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 Abstract 
 Background: Because of changing world demographics, the 
elderly population is steadily increasing. Few studies have 
assessed the prevalence of atopy and allergic diseases in el-
derly persons with objective measures. The aim of this paper 
is to describe the prevalence of atopy, self-reported allergic 
rhinitis and doctor’s diagnosed asthma in persons over the 
age of 60 in Switzerland.  Methods: The cross-sectional ex-
amination of the Swiss Study on Air Pollution and Health in 
Adults (SAPALDIA 1), performed in 1991, included 9,651 
adults aged 18–60 years. In 2001–2002 the same subjects 
were invited for a follow-up examination (SAPALDIA 2). Se-
rum samples collected at baseline and follow-up were tested 
for specific IgE sensitization with the Phadiatop ® (Phadia, 
Uppsala, Sweden, now Thermo Fisher Scientific) assay con-
taining a mixture of common respiratory allergens (grass, 
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mates, the prevalence of allergic rhinitis among persons 
aged between 60 and 70 years in Switzerland in the present 
cohort is of the order of 13–15% and should not be underes-
timated, although it is lower than in age groups  ≤ 60 years. 
 Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 On the basis of a MEDLINE search using the terms 
‘epidemiology and allergy’ it was stated that there was a 
lack of research on the incidence and prevalence of aller-
gic sensitization in the elderly population  [1] . In fact, al-
though in their daily work allergists see more and more 
elderly patients with rhinitis, asthma and other allergic 
diseases, few studies have assessed the prevalence of atopy 
and allergic diseases in elderly patients with objective 
measures such as skin prick tests to aeroallergens or food 
allergens or serum IgE determination  [2–6] . Because of 
changing world demographics, it is estimated that the el-
derly population will increase by 75% between 2010 and 
2030  [7] .
 SAPALDIA (Swiss Study on Air Pollution and Lung 
Diseases in Adults) was initiated in 1991 in the Swiss pop-
ulation aged 18–60 years, with the primary aims of inves-
tigating the prevalence of respiratory and allergic diseases 
and their associations with air pollution (SAPALDIA 1) 
 [8–11] . The same subjects were invited for a second ex-
amination in 2001–2002 (SAPALDIA 2)  [12–15] . Serum 
samples from the formal biobank established at follow-up 
were analyzed for specific IgE against  the eleven most 
common inhalant allergens in one pool (Phadiatop ® as-
say; Phadia, Uppsala, Sweden, now Thermo Fisher Scien-
tific). The aim of this study was to assess the prevalence 
rates of atopy (defined as a positive result in the Phadi-
atop) allergic rhinitis and asthma among participants 
who were aged between 60 and 72 years in SAPALDIA 2 
(see Appendix for details of the SAPALDIA team).
 Material and Methods 
 Study Population 
 The baseline assessment of the SAPALDIA study was car-
ried  out during 1991–1992 in eight Swiss areas with different 
environmental characteristics (SAPALDIA 1). Participants aged 
18–60 years were recruited based on random samples selected 
from inhabitant registries. The samples were composed to reflect 
the general Swiss population in urban and rural areas. A baseline 
participation rate of 80% was achieved. Complete allergy skin 
and in vitro tests as well as data derived from a health question-
naire were available from 8,357 out of 9,651 baseline partici-
pants. The same subjects participating in 1991 were reinvited for 
a follow-up examination (SAPALDIA 2) between July 2001 and 
February 2002. With few exceptions, the same examinations 
were conducted again in SAPALDIA 2. Blood was sampled at 
both baseline and follow-up examination. The methods in SA-
PALDIA 1 and 2 have been described in detail elsewhere  [8–10, 
12, 13] .
 Assessment of Atopy, Allergic Rhinitis and Asthma 
 The serum samples were tested with Phadiatop which contains 
a mixture of common respiratory allergens (grass, birch, mugwort, 
Parietaria, olive, dog, cat, horse,  Cladosporium herbarum , house 
dust mite and flour mite). Positive reaction was defined as pro-
posed by the manufacturer. All serum testing for IgE was done in 
the Allergy Laboratory of the Department of Dermatology, Uni-
versity Hospital Zurich by the same technicians. Individuals with 
a positive result in the Phadiatop test were classified as atopic. 
Based on the questionnaire answers, ‘self-reported current allergic 
rhinitis’ was defined by a positive answer to the question, ‘Do you 
have any nasal allergies including hay fever?’ ‘Asthma’ was defined 
as positive answers to both questions, ‘Have you asthma?’ and 
‘Was asthma confirmed by a doctor?’
 Statistical Analyses 
 The raw prevalences of atopy, self-reported allergic rhinitis and 
asthma were assessed for the age groups  ≤ 60 years and >60 years, 
for men and women, separately. Differences in prevalence rates 
between age groups were assessed by Fisher’s exact test. In a sen-
sitivity analysis, nonparticipants of SAPALDIA 2 were also includ-
ed, assuming that their symptom status would not have changed 
between the two surveys.
 Results 
 A total of 7,667 subjects (men = 3,692/women = 
3,975)  participated in the SAPALDIA follow-up study 
(SAPALDIA 2) and responded to a detailed question-
naire (80% of SAPALDIA 1 participants). For 5,835 sub-
jects (men = 2,839/women = 2,996) Phadiatop results 
were available at follow-up. Atopy results were available 
for 5,463 participants from both time points. According 
to  table 1 the crude prevalence rates of atopy (Phadiatop 
positivity) among SAPALDIA 2 (2001/2002) participants 
(n = 5,463) over the age of 60 was 22%. As SAPALDIA 1 
Table 1.  Crude prevalence rates of atopy (Phadiatop positivity) 
among SAPALDIA 1 (1991/92) and SAPALDIA 2 (2001/02) par-
ticipants <60 and >60 years (n = 5,463)
Age class category, years SAPALDIA 1 SAPALDIA 2
<60 29% 33%
>60 – 22%
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studied the Swiss population aged 18–60 years, the rate 
over the age of 60 could not have been  assessed at the 
baseline examination of the cohort in 1991. The rate un-
der the age of 60 was 29%; there was also a slight increase 
in SAPALDIA 2 in this age group to 33%. Among subjects 
aged 60 years or more in SAPALDIA 2, the incidence 
rates of new atopy from SAPALDIA 1 to SAPALDIA 2 
were 7.2% (39/538) in men and 4.0% (26/656) in women, 
and the remission rates were 22.5% (46/204) in men and 
22.4% (35/156) in women.  Table 2 compares the gender-
specific prevalence rates at follow-up for atopy, self-re-
ported current allergic rhinitis and doctor’s diagnosed 
asthma in the age groups  ≤ 60 versus >60 years. The atopy 
prevalence rates were 36.4% in the men aged  ≤ 60 versus 
26.2% in the men aged >60 years. Corresponding rates 
in  women were 30.6% and 18.1%, respectively (both 
p < 0.001). The prevalence rates for self-reported allergic 
rhinitis in subjects >60 years were 13.0% for men and 
15.4% for women (p = 0.12), and for doctor’s diagnosed 
asthma 6.6% and 7.6%, respectively (p = 0.40). For both 
self-reported diseases, rates were higher among per-
sons <60 years. After imputation of self-reported allergic 
rhinitis and asthma for SAPALDIA 2 nonparticipants 
the prevalence rates were not substantially different ( ta-
ble 3 ).
 To address the question of whether the high preva-
lence observed at age 60+ is the result of a birth cohort 
effect, we conducted a logistic regression analysis for 
Phadiatop positivity including birth year, birth year 
squared and an indicator variable for subjects aged 
60 years or more in SAPALDIA 2 as independent vari-
ables. There was some indication of a slight slowing of the 
general trend of decreasing atopy with increasing age of 
the birth cohort. However, the indicator variable for sub-
jects aged 60+ in SAPALDIA 2 was highly insignificant in 
this model, showing that these oldest birth cohorts fitted 
well into the overall pattern. 
 Discussion 
 Our findings show a high prevalence of allergic rhi-
nitis in the elderly (13% in men and 15% in women). 
Prevalence rates of IgE-mediated sensitization and, 
Table 2.  Gender-specific prevalence rates of atopic sensitization, self-reported current allergic rhinitis and doctor’s diagnosed asthma in 
SAPALDIA 2 (2001–2003) participants <60 and >60 years
Men
≤60 yearsa, %
Men
>60 yearsa, %
Women
≤60 yearsa, %
Women
>60 yearsa, %
Sex differences
p values
Atopy (Phadiatop positive)
men = 2,839/women = 2,996 36.4 26.6*** 30.6 18.1*** both <0.001
Allergic rhinitis
men = 3,692/women = 3,975 21.6 13.0*** 24.5 15.4*** 0.01/0.12
Diagnosed asthma
men = 3,693/women = 3,974 8.3 6.6 8.4 7.6 0.88/0.40
 *** p < 0.001 for difference in prevalence rate between age groups (Fisher’s exact test).
a At follow-up assessment in 2002.
Table 3.  Gender-specific self-reported allergic rhinitis and asthma at SAPALDIA 2, including data from SAPALDIA 2 nonparticipants
Men
≤60 yearsa, %
Men
>60 yearsa, %
Women
≤60 yearsa, %
Women
>60 yearsa, %
Allergic Rhinitis
men = 4,744/women = 4,906 20.4 13.2 22.7 15.1
Diagnosed asthma
men = 4,744/women = 4,906 8.2 6.7 8.4 7.4
 Symptom status was carried forward from SAPALDIA 1 and age was imputed by adding 11 years to age at SAPALDIA 1.
a At follow-up assessment in 2002.
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therefore, presence of atopy (Phadiatop positive) were 
even higher, with 26.2% in men and 18.1% in women 
(both p < 0.001). There is no indication that these high 
prevalence rates might have resulted from a birth co-
hort effect.
 Some allergens that are important in certain regions 
such as cypress, ragweed or Alternaria might be missed 
by Phadiatop. However, cypress pollen is not reported 
in  relevant numbers in Switzerland and ragweed pol-
len plays a role only in some very limited areas such as 
Geneva or Ticino, as reported  [14, 15] .
 The prevalence of sensitization against Alternaria is 
quite low in Switzerland with about 1.7% (unpublished 
own results from a study with skin prick tests on 331 pa-
tients); however, some of these patients indeed might be 
missed with Phadiatop and the sensitization rate might 
therefore be even slightly higher.
 The results of our study are in line with the few results 
published to date about the relatively high prevalence of 
atopy and allergic diseases in the elderly population. In 
the 1990s, Kerkhof et al.  [15] reported age- and sex-spe-
cific data on the prevalence of specific IgE tests to com-
mon aeroallergens in a random sample of 2,496 subjects 
aged 20–70 years from the Dutch general population. In 
the 60- to 70-year-old age group, the prevalence of at 
least 1 positive specific IgE test was 19% in men and 21% 
in women. In a study of an unselected Swiss population 
performed in 1986, it was shown that more than 4% still 
had hay fever and other atopic diseases after their 60th 
birthday  [16] . PAQUID (Personnes Agées QUID), a co-
hort of randomly selected subjects over the age of 65 liv-
ing at home in the South-West of France  [5] , included 
158 men (45%; mean age 74 ± 5 years) and 194 women 
(55%; mean age 75 ± 7 years). The atopic status was also 
assessed in vitro by Phadiatop determination. There 
were 42 (11.9%) subjects with a positive Phadiatop test, 
and the test was uncertain in 2.3% of subjects (n = 8). The 
proportion with atopy was similar in men (13.9%) and 
women (10.3%).
 In Portugal, the prevalence of allergic rhinitis was 
evaluated in a cross-sectional, population-based study of 
6,859 subjects aged 16–95 years by questionnaire. Differ-
ent rhinitis subtypes were assessed by applying the clini-
cal criteria of the new ARIA classification (intermittent 
and persistent rhinitis), including differences or similar-
ities in demography among others  [17] . The estimated 
prevalence of rhinitis was 26.1% (48% for intermittent 
vs. 52% for persistent rhinitis). This study also included 
individuals older than 65 years. The prevalence of rhini-
tis found in this elderly group (25.9%) did not differ from 
the prevalence found in younger participants. In fact el-
derly persons presented rhinitis prevalence (for persis-
tent and intermittent types) similar to nonelderly adult 
study subjects.
 A recent longitudinal study with 20 years of follow-
up (1989–2008) performed in Legnano, Northern Italy, 
focused on Ambrosia allergy. In 1999, 13.7% of the pa-
tients exhibiting a sensitization to Ambrosia pollen were 
older than 50  [18] . In 2006, this percentage increased 
to 30.4%. In contrast, the percentage of grass pollen-sen-
sitized patients older than 50 remained stable over time 
(9.3% in 1999 and 9.5% in 2006). The percentage of the 
Ambrosia-sensitized patients older than 60 years was 
smaller but, nevertheless, there was an increase from 
5.8% in 1999 to 9.5% in 2006. Grass pollen-sensitized 
persons over the age of 60 made up 3.5% and 4.1% in 
1999 and 2006, respectively. Exposure of the general 
population in an area to new airborne allergens resulted 
in the onset of respiratory allergy in many older people 
who lacked any relevant predisposing factor, as was 
shown also for the area north of Milan during a period 
of 15 years  [19] .
 A novel aspect of our study is the observed small dif-
ference between atopic and allergic women (18 vs. 
15.4%) over the age of 60, as generally many atopic sub-
jects do not  develop clinical allergy. When looking 
at  the sensitivity  and specificity of a positive Phadi-
atop  test result as predictor of allergic rhinitis in the 
SAPADLIA 2 sample, it turned out that the group of 
women aged 60+ was different  from the other three 
groups. Sensitivity in this group was only 57% com-
pared to values of over 70% in the other three groups, 
while specificity was higher with 91% compared to 82% 
in the other three groups. We are planning for  atopy 
analyses in blood collected at the third follow-up of the 
SAPALDIA cohort. As detailed information on hor-
monal and reproductive factors was obtained during 
that follow-up, we will be able to investigate potential 
reasons underlying the observed differences in test sen-
sitivity and specificity. At this point in time we can only 
speculate that this age and gender group may be more 
sensitive to clinical allergy or may differ with regard to 
symptom reporting.
 In conclusion, the few available descriptive studies 
demonstrate that the prevalence of atopic sensitizations 
and atopic diseases ranges between 12 and 25% after the 
age of 60 years. Atopy thus remains a clinically relevant 
problem in this age group. Also, elderly people can de-
velop allergic sensitization and allergic diseases, even if 
their proportion is lower than for younger people.
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 Appendix 
 The SAPALDIA Team 
 Study Directorate 
 T. Rochat (p), J.M. Gaspoz (c), N. Künzli (e/exp), L.J.S. Liu 
(exp), N.M. Probst-Hensch (e/g), C. Schindler (s).
 Scientific Team 
 J.C. Barthélémy (c), W. Berger (g), R. Bettschart (p), A. Bircher 
(a), G. Bolognini (p), O. Brändli (p), C. Brombach (n), M. Brutsche 
(p), L. Burdet (p), M. Frey (p), U. Frey (pd), M.W. Gerbase (p), D. 
Gold (e/c/p), E. de Groot (c), W. Karrer (p), R. Keller (p), B. Knöp-
fli (p), B. Martin (pa), D. Miedinger (o), U. Neu (exp), L. Nicod (p), 
M. Pons (p), F. Roche (c), T. Rothe (p), E. Russi (p), P. Schmid-
Grendelmeier (a), A. Schmidt-Trucksäss (pa), A. Turk (p), J. 
Schwartz (e), D. Stolz (p), P. Straehl (exp), J.M. Tschopp (p), A. 
von Eckardstein (cc), E. Zemp Stutz (e).
 Scientific Team at Coordinating Centers 
 M. Adam (e/g), E. Boes (g), P.O. Bridevaux (p), D. Carballo (c), 
E. Corradi (e), I. Curjuric (e), J. Dratva (e), A. Di Pasquale (s), L. 
Grize (s), D. Keidel (s), S. Kriemler (pa), A. Kumar (g), M. Im-
boden (g), N. Maire (s), A. Mehta (e), F. Meier (e), H. Phuleria 
(exp), E. Schaffner (s), G.A. Thun (g) A. Ineichen (exp), M. Raget-
tli (exp), M. Ritter (exp), T. Schikowski (e), G. Stern (pd), M. Tar-
antino (s), M. Tsai (exp), M. Wanner (pa).
 (a) allergology, (c) cardiology, (cc) clinical chemistry, (e) epi-
demiology, (exp) exposure, (g) genetic and molecular biology, (m) 
meteorology, (n) nutrition, (o) occupational health, (p) pneumol-
ogy, (pa) physical activity, (pd) pediatrics, (s) statistics.
 Administrative Staff 
 C. Gabriel, R. Gutknecht.
 The study could not have been done without the help of 
the  study participants, technical and administrative support 
and the medical teams and field workers at the local study sites. 
Local  fieldworkers : Aarau: S. Brun, G. Giger, M. Sperisen, M. 
Stahel. Basel: C. Bürli, C. Dahler, N. Oertli, I. Harreh, F. Karrer, 
G. Novicic, N. Wyttenbacher. Davos: A. Saner, P. Senn, R. Win-
zeler, Geneva: F. Bonfils, B. Blicharz, C. Landolt, J. Rochat. Lu-
gano: S. Boccia, E. Gehrig, M.T. Mandia, G. Solari, B. Viscardi. 
Montana: A.P. Bieri, C. Darioly, M. Maire. Payerne: F. Ding, P. 
Danieli, A. Vonnez. Wald: D. Bodmer, E. Hochstrasser, R. Kunz, 
C. Meier, J. Rakic, U. Schafroth, A. Walder.
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